OVERVIEW

Evaluating Clinical Pathways for Ovarian Cancer Treatment and Maintenance Therapy is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Nov 21, 2018 - Nov 21, 2019.

Intended Learners:
This activity is designed for directors of oncology practice programs and cancer centres, oncologists, haematologists, commercial and government payers, pathway development executives, reimbursement specialists, speciality pharmacists, HEOR specialists, and other healthcare professionals interested in learning how to implement, integrate, and measure treatment pathways.

Accreditation:
CME: Naccme Designates This Enduring Material For A Maximum Of 0.50 Ama Pra Category 1 Credits™. Physicians Should Claim Only The Credit Commensurate With The Extent Of Their Participation In The Activity.

Physician Assistants: Naccme Has Been Authorized By The American Academy Of Pas (Aapa) To Award Aapa Category 1 CME Credit For Activities Planned In Accordance With The Aapa Cme Criteria. This Activity Is Designated For 0.50 Aapa Category 1 Credit(S). Pas Should Only Claim Credit Commensurate With The Extent Of Their Participation In The Activity.

CNE: This Continuing Nursing Education Activity Awards 0.50 Contact Hours. Provider Approved By The California Board Of Registered Nursing, Provider #13255 For 1.50 Contact Hours.

Nursing Pharmacology Hours: This Continuing Nursing Educational Activity Awards Up To 0.50 Pharmacology Hours.

Learning Objectives:
After Completing This Activity, Participants Should Be Able To:
• Outline the clinical and socioeconomic burdens of recurrent ovarian cancer and the goals of remission maintenance that can be addressed by clinical pathways
• Describe the challenges associated with clinical pathway design and implementation across ovarian cancer disease settings and the importance of tailoring pathways
• Discuss the implications of BRCA mutational status, BRCAness, synthetic lethality, and within-class differences in the mechanisms of action, efficacy and safety, and indications of available and emerging PARP inhibitors for optimal ovarian cancer pathway integration
• Apply the latest clinical data and guideline recommendations to strategies for the optimal integration of PARP inhibitors into clinical pathways for ovarian cancer across disease settings.

Activity Overview:
• This on-demand webcast is available with synchronized slides and audio.
• To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.
• After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
• Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.